<SEC-DOCUMENT>0001193125-17-312708.txt : 20171018
<SEC-HEADER>0001193125-17-312708.hdr.sgml : 20171018
<ACCEPTANCE-DATETIME>20171018165202
ACCESSION NUMBER:		0001193125-17-312708
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20171018
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171018
DATE AS OF CHANGE:		20171018

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HCA Healthcare, Inc.
		CENTRAL INDEX KEY:			0000860730
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062]
		IRS NUMBER:				273865930
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11239
		FILM NUMBER:		171143035

	BUSINESS ADDRESS:	
		STREET 1:		ONE PARK PLZ
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		6153449551

	MAIL ADDRESS:	
		STREET 1:		ONE PARK PLAZA
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HCA Holdings, Inc.
		DATE OF NAME CHANGE:	20101126

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HCA INC/TN
		DATE OF NAME CHANGE:	20010627

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HCA THE HEALTHCARE CO
		DATE OF NAME CHANGE:	20010419
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d469505d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): October 18, 2017 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>HCA HEALTHCARE, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-11239</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">27-3865930</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>One Park Plaza, Nashville,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tennessee</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>37203</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (615)&nbsp;344-9551 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company &nbsp;&nbsp;&nbsp;&nbsp;&#9744;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &nbsp;&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2.02. Results of Operations and Financial Condition. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 18, 2017, HCA Healthcare, Inc. (the &#147;Company&#148;) issued a press release announcing, among other matters, its preliminary
results of operations for the third quarter ended September 30, 2017, the text of which is set forth as <U>Exhibit 99.1</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01.
Regulation FD Disclosure. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October 18, 2017, the Company issued a press release announcing, among other matters, its preliminary
results of operations for the third quarter ended September 30, 2017, the text of which is set forth as <U>Exhibit 99.1</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial
Statements and Exhibits. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits: </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><A HREF="d469505dex991.htm">Press Release, dated October 18, 2017. </A></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HCA HEALTHCARE, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ William B. Rutherford</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William B. Rutherford</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President&nbsp;and Chief Financial Officer</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: October 18, 2017 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d469505dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">


<IMG SRC="g469505img1.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<IMG SRC="g469505img2.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>FOR IMMEDIATE RELEASE</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>INVESTOR CONTACT:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>MEDIA CONTACT:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mark Kimbrough</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ed Fishbough</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">615-344-2688</FONT></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">615-344-2810</FONT></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>HCA Previews 2017 Third Quarter Results </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nashville, Tenn., October</B><B></B><B>&nbsp;18, 2017&#150; </B>HCA Healthcare, Inc. (NYSE: HCA) today announced preliminary financial and operating
results for its third quarter ended September&nbsp;30, 2017. The financial results are subject to finalization of the Company&#146;s quarterly financial and accounting procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HCA anticipates revenues for the third quarter of 2017 to approximate $10.696&nbsp;billion compared to $10.270&nbsp;billion in the third quarter of 2016. Net
income attributable to HCA Healthcare, Inc. for the third quarter is expected to approximate $426&nbsp;million, or $1.15 per diluted share, compared to $618&nbsp;million, or $1.59 per diluted share, in the third quarter of 2016. Results for the
third quarter of 2017 include losses on retirement of debt of $39&nbsp;million, or $0.07 per diluted share. Adjusted EBITDA for the third quarter of 2017 is expected to approximate $1.776&nbsp;billion compared to $1.957&nbsp;billion in the previous
year&#146;s third quarter. Adjusted EBITDA is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure. A table reconciling expected net income attributable to HCA Healthcare, Inc. to expected Adjusted EBITDA is included in this release.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the third quarter of 2017, the Company incurred additional expenses and experienced losses of revenues estimated at approximately
$140&nbsp;million, or $0.24 per diluted share, associated with hurricanes Harvey and Irma&#146;s impact on our Corpus Christi, Houston, Florida, Georgia and South Carolina facilities. This amount is prior to any insurance recoveries which the
Company may receive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, results for the third quarter of 2017 include a negative impact to operating results related to the Texas Medicaid Waiver
program of approximately $50&nbsp;million, or $0.08 per diluted share. This reflects final settlement amounts related to the program year ended September&nbsp;30, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Same facility admissions for the third quarter of 2017 increased 0.6&nbsp;percent, while same facility equivalent admissions increased 0.3&nbsp;percent, when
compared to the third quarter of 2016. Same facility emergency room visits for the third quarter of 2017 increased 0.3&nbsp;percent from the prior year&#146;s third quarter. The Company estimates that hurricanes had unfavorable impacts of 30 basis
points on same facility admissions growth, 80 basis points on same facility equivalent admissions growth and 30 basis points on same facility emergency visits growth during the third quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Same facility revenue per equivalent admission is expected to increase approximately 2.0&nbsp;percent in the third quarter of 2017 compared to the prior
year&#146;s third quarter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial impact of the hurricanes and the Texas Medicaid Waiver program were not reflected in our previous
guidance. The Company&#146;s 2017 guidance ranges for the year have been updated from our July&nbsp;25, 2017 second quarter release and are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="60%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:129.20pt; font-size:10pt; font-family:Times New Roman">2017 Updated Guidance Ranges</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$43.0 to $44.0&nbsp;billion</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$8.00 to $8.15&nbsp;billion</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EPS (diluted)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$6.45 to $6.70 per diluted share</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capital Expenditures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Approximately $3.0&nbsp;billion</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s 2017 updated guidance contains a number of assumptions, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2017 guidance for EPS (diluted) includes an estimated $90&nbsp;million income tax benefit, or $0.24 per diluted share, related to the accounting standard which requires the recording of excess tax benefits related to
employee equity award settlements as a component of the provision for income taxes. The timing and amounts related to employee equity award settlements are difficult to project and may vary from this estimate. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2017 guidance includes expected full-year earnings for the Company&#146;s Oklahoma facilities which are under agreement to be sold. The Company cannot at this time estimate a closing date. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2017 guidance includes the impact of acquisitions completed as of September&nbsp;30, 2017. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2017 guidance excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claim costs and impairments of long-lived assets. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA is a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measure. A table reconciling net income attributable to HCA Healthcare, Inc.
to Adjusted EBITDA is included in this release. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s updated guidance is based on current plans and expectations and is subject to a number
of known and unknown uncertainties and risks, including those set forth below in the Company&#146;s &#147;Forward-Looking Statements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HCA
anticipates reporting its complete financial and operating results for the third quarter of 2017 on, or about, October&nbsp;31, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Forward-Looking Statements </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release
contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company&#146;s expected results for the third quarter of 2017, the Company&#146;s
financial guidance for the year ending December&nbsp;31, 2017, as well as other statements that do not relate solely to historical or current facts, and are subject to finalization of the Company&#146;s third quarter financial and accounting
procedures. Forward-looking statements can be identified by the use of words like &#147;may,&#148; &#147;believe,&#148; &#147;will,&#148; &#147;expect,&#148; &#147;project,&#148; &#147;estimate,&#148; &#147;anticipate,&#148; &#147;plan,&#148;
&#147;initiative&#148; or &#147;continue.&#148; These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which
could significantly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1)&nbsp;the impact of our substantial
indebtedness and the ability to refinance such indebtedness on acceptable terms, (2)&nbsp;the impact of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#147;Health
Reform Law&#148;), including the effects of any repeal of, or changes to, the Health Reform Law or changes to its implementation, the possible enactment of additional federal or state health care reforms and possible changes to other federal, state
or local laws or regulations affecting the health care industry, (3)&nbsp;the effects related to the continued implementation of the sequestration spending reductions required under the Budget Control Act of 2011 (the &#147;BCA&#148;), and related
legislation extending these reductions, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (4)&nbsp;increases in the
amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (5)&nbsp;the ability to achieve operating and financial targets, and attain expected levels of patient volumes and control the costs
of providing services, (6)&nbsp;possible changes in Medicare, Medicaid and other state programs, including Medicaid upper payment limit programs or waiver programs, that may impact reimbursements to health care providers and insurers, (7)&nbsp;the
highly competitive nature of the health care business, (8)&nbsp;changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under managed care agreements, the ability to enter into and renew
managed care provider agreements on acceptable terms and the impact of consumer driven health plans and physician utilization trends and practices, (9)&nbsp;the efforts of insurers, health care providers and others to contain health care costs,
(10)&nbsp;the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (11)&nbsp;increases in wages and the ability to attract and retain qualified management and personnel,
including affiliated physicians, nurses and medical and technical support personnel, (12)&nbsp;the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (13)&nbsp;changes in accounting
practices, (14)&nbsp;changes in general economic conditions nationally and regionally in our markets, (15)&nbsp;the emergence and effects related to infectious diseases, (16)&nbsp;future divestitures which may result in charges and possible
impairments of long-lived assets, (17)&nbsp;changes in business strategy or development plans, (18)&nbsp;delays in receiving payments for services provided, (19)&nbsp;the outcome of pending and any future tax audits, disputes and litigation
associated with our tax positions, (20)&nbsp;potential adverse impact of known and unknown government investigations, litigation and other claims that may be made against us, (21)&nbsp;the impact of potential cybersecurity incidents or security
breaches, (22)&nbsp;our ongoing ability to demonstrate meaningful use of certified electronic health record technology, and (23)&nbsp;other risk factors described in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year
ended December&nbsp;31, 2016 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties
inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management&#146;s views only as of the date hereof. We undertake no obligation to revise or update any
forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All references to &#147;Company&#148; and &#147;HCA&#148; as used throughout this release refer to HCA
Healthcare, Inc. and its affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HCA Healthcare, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Supplemental <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Disclosures </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Operating Results Summary </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Dollars in millions, except per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Third Quarter</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,696</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,270</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to HCA Healthcare, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>426</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>618</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains on sales of facilities (net of tax)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Losses on retirement of debt (net of tax)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>25</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal claim costs (net of tax)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, losses on
retirement of debt and legal claim costs (a)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>447</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>625</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>539</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>495</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>427</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>432</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>259</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>278</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to noncontrolling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>104</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA (a)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,776</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,957</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA margin (a)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16.6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19.1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted earnings per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to HCA Healthcare, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1.15</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1.59</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gains on sales of facilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(0.01</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(0.01</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Losses on retirement of debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.07</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.01</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal claim costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.02</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, losses on
retirement of debt and legal claim costs(a)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1.21</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1.61</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing diluted earnings per share (millions)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>369.834</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>389.592</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s forecasted operating results are based on current expectations and are subject to finalization of the
Company&#146;s third quarter financial and accounting procedures. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, losses on retirement of debt and legal claim costs, and Adjusted EBITDA should not be considered as measures of financial
performance under generally accepted accounting principles (&#147;GAAP&#148;). We believe net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, losses on retirement of debt and legal claim costs, and Adjusted
EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies
upon net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, losses on retirement of debt and legal claim costs, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health
care facilities and their management teams. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Management and investors review both the overall performance (including net
income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, losses on retirement of debt and legal claim costs, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our
health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year
and to compare our operating results with other companies in the health care industry. It is reasonable to expect that gains on sales of facilities, losses on retirement of debt and legal claim costs will occur in future periods, but the amounts
recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care
companies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, losses on retirement of debt and legal
claim costs, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from
operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, losses on retirement of debt and legal claim costs, and Adjusted EBITDA are not
measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., excluding gains on sales of facilities, losses on retirement of debt and legal claim costs, and Adjusted
EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.&nbsp;&nbsp;&nbsp;&nbsp; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HCA Healthcare, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Supplemental Non-GAAP Disclosures </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2017 Operating Results Forecast </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Dollars in millions, except per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ending<BR>December&nbsp;31, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>43,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to HCA Healthcare, Inc. (a)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,495</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,110</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,120</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,690</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,700</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,290</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,325</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to noncontrolling interests</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>510</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA (a) (b)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,150</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted earnings per share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to HCA Healthcare, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6.45</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6.70</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing diluted earnings per share (millions)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>372.400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>372.400</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s forecasted guidance range is based on current plans and expectations and is subject to a number of known
and unknown uncertainties and risks. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">The Company does not forecast the impact of items such as, but not limited to, losses (gains) on sales of facilities, losses on retirement of debt, legal claim costs (benefits) and impairments of long-lived assets,
because the Company does not believe that it can forecast these items with sufficient accuracy. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles (&#147;GAAP&#148;). We believe Adjusted EBITDA is an important measure that supplements
discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon Adjusted EBITDA as a primary measure to
review and assess operating performance of its health care facilities and their management teams. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Management and investors
review both the overall performance (including net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by
revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income attributable
to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is
susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g469505img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g469505img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 6 #X P$1  (1 0,1 ?_$ -L   $$ @,! 0
M       ("0H+ 0<" P0%!@$  @(# 0$               <%!@$#! (($
M!@$# 00#!PH0" \    ! @,$!08' !$("2$Q$A-!40IA@<$B%!46<9&AX3(C
MMW@Y&K%RTE24M-16EM87=]<8F%E"PC,D=#<X6/#14H)#8S2$U39&)V>'*!$
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MD,U?!1!UC\GYB^S/1WH^.TWVU@WM+?1W(43FY,SI2%#Q&.;".:2E OK$1HH
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M<XN<7.)))5E5[+)Q<C,)]-B.S6[C@2N?+&]V/(D@\5;$;KA1Z3(/,=X]CBD
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M1P\,1_S&P<PZPJ_F6:#,+T((&(^'-_'J*;DQ-[':PM&-:'/9@YF6BF9+F*?
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M$4%T%5&#CY*[(DNFJ=NX%%)P"#@A#"9NO\G734\!]C>!0IMO"8HB(7<HJ1(
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M2@;'7)-K,P<RP5!B)2O(R49)+IB8# !TP';6Z:9(3K/+T0N49)NGI%T2+58
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623(F CZQ @  CKP277F*]  7""__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g469505img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g469505img2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 0@#$ P$1  (1 0,1 ?_$ (D   (# 0 # 0
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M0'7U;+W*BYS$\CA6KVLN#+]>5'*S4CQHE<L@"SQ95VRKIW&ODD7JD;9)EXV
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M-<^8+8;$>;ZYM)6,%,\9882Q4M7)O%,K?7,NY)=[7;C324FPO=62:(&2LA$
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
